A5036190568- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes and associated disorders
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Genetic Associations and Epidemiology
- Diet, Metabolism, and Disease
- Liver Disease Diagnosis and Treatment
- Lipoproteins and Cardiovascular Health
- Pancreatitis Pathology and Treatment
- Cancer, Hypoxia, and Metabolism
- Adrenal Hormones and Disorders
- Adipose Tissue and Metabolism
- Chronic Kidney Disease and Diabetes
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cardiovascular Health and Disease Prevention
- Lipid metabolism and disorders
- Neuropeptides and Animal Physiology
- Neuroendocrine Tumor Research Advances
- Neutropenia and Cancer Infections
- Adipokines, Inflammation, and Metabolic Diseases
- Peroxisome Proliferator-Activated Receptors
Kawasaki Medical School
2016-2025
Kawasaki Medical School Hospital
2014-2024
Kurashiki Medical Center
2021-2023
Weatherford College
2013-2022
Kawasaki Hospital
2014-2021
Kawasaki University of Medical Welfare
2021
Niigata Institute of Technology
2018-2020
Kyushu University
2013-2015
Nihon University
2012
Kobe University
2012
In recent years, several oral antidiabetic drugs with new mechanisms of action have become available, expanding the number treatment options. Sodium/glucose cotransporter-2 (SGLT2) inhibitors are a class an insulin-independent mechanism promoting urinary glucose excretion. We report results combined Phase 2 and 3 clinical study (Japic CTI-101349) SGLT2 inhibitor tofogliflozin (CSG452, RG7201) in Japanese patients type diabetes mellitus. The efficacy safety were assessed this multicenter,...
OBJECTIVE—Recently, several genes have been shown to be associated with an increased risk of type 2 diabetes by genome-wide association studies in white populations. To further investigate the involvement these polymorphisms conferring susceptibility diabetes, we examined 14 single nucleotide (SNPs) within 11 candidate loci a Japanese population. RESEARCH DESIGN AND METHODS—We analyzed SNPs (rs4402960 IGF2BP2, rs10811661 CDKN2A/B, rs1111875 and rs7923837 HHEX, rs13266634 SLC30A8, rs1113132...
To search for a gene(s) conferring susceptibility to diabetic nephropathy (DN), we genotyped over 80,000 gene-based single nucleotide polymorphisms (SNPs) in Japanese patients and identified that the engulfment cell motility 1 gene (ELMO1) was likely candidate DN, view of significant association an SNP this with disease (intron 18+9170, GG vs. GA+AA, χ2 = 19.9, P 0.000008; odds ratio 2.67, 95% CI 1.71–4.16). In situ hybridization (ISH) using kidney normal mice revealed ELMO1 expression...
Strategies aimed at mimicking or enhancing the action of incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve glucose-stimulated insulin secretion (GSIS); however, it is not clear whether GLP-1 directly drives in pancreatic islets. Here, we examined mechanisms by which stimulates mouse and human We found that enhances GSIS a half-maximal effective concentration 0.4 pM. Moreover, determined activates PLC, increases submembrane diacylglycerol thereby PKC, resulting membrane...
Although over 60 loci for type 2 diabetes (T2D) have been identified, there still remains a large genetic component to be clarified. To explore unidentified T2D, we performed genome-wide association study (GWAS) of 6 209 637 single-nucleotide polymorphisms (SNPs), which were directly genotyped or imputed using East Asian references from the 1000 Genomes Project (June 2011 release) in 5976 Japanese patients with T2D and 20 829 nondiabetic individuals. Nineteen unreported selected taken...
We investigated the molecular mechanism by which human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice. Male and m/m mice aged 10 weeks received or vehicle for 2 days weeks. In addition to morphological biochemical analysis of islets, gene expression profiles islet core area were laser capture microdissection real-time RT-PCR. Liraglutide treatment improved metabolic variables insulin sensitivity also increased glucose-stimulated secretion...
Dapagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor under development as treatment for type diabetes mellitus (T2DM). This study assessed the efficacy and safety of dapagliflozin monotherapy in Japanese T2DM patients with inadequate glycaemic control.Patients (n = 279) were randomized to receive (1, 2.5, 5 or 10 mg/day) placebo once daily 12 weeks. The primary endpoint was change from baseline haemoglobin A1c (HbA1c) at week 12. Secondary endpoints included fasting...
Aim To assess the efficacy and safety of fasiglifam 25 50 mg in J apanese patients with type 2 diabetes inadequately controlled by diet exercise. Methods This phase III , double‐blind, placebo‐controlled, multicentre study included 192 randomized to once‐daily treatment (n = 63) or 62) placebo 67) for 24 weeks. The primary endpoint was change from baseline glycated haemoglobin ( HbA1c ) at week 24. Results At 24, both groups had significantly reduced levels compared group (p < 0.0001)....
Sodium glucose co-transporter 2 (SGLT2) inhibitors exhibit diuretic activity, which is a possible mechanism underlying the cardiovascular benefit of these inhibitors. However, osmotic diuresis-induced increase in urine volume, and risk dehydration have been concern with SGLT2 inhibitor treatment. This study aimed to investigate canagliflozin-induced diuresis Japanese type diabetes mellitus (T2DM) patients. Thirteen T2DM patients received daily oral dose 100 mg canagliflozin before breakfast...
In the EMPA-REG OUTCOME®trial, empagliflozin added to standard of care reduced risk 3-point major adverse cardiovascular (CV) events (3-point MACE: composite CV death, non-fatal myocardial infarction, or stroke) by 14%, death 38%, hospitalization for heart failure 35%, and all-cause mortality 32% in patients with type 2 diabetes (T2DM) established disease. We investigated effects Asian race.Methods Results:Patients were randomized receive 10 mg, 25 placebo. Of 7,020 treated, 1,517 (21.6%)...
To identify a novel susceptibility locus for type 2 diabetes, we performed an imputation-based, genome-wide association study (GWAS) in Japanese population using newly obtained imputed-genotype data 229 890 single-nucleotide polymorphisms (SNPs) estimated from previously reported, directly genotyped GWAS the same samples (stage 1: 4470 diabetes versus 3071 controls). We 43 new SNPs with P-values of <10(-4) part stage-1 (2692 controls), and associations validated were evaluated another 11 139...
To evaluate the efficacy and safety of selective sodium glucose co-transporter 2 inhibitor dapagliflozin in Japanese patients with type diabetes mellitus (T2DM) inadequately controlled by diet exercise.Patients received placebo or (5 10 mg) once daily for 24 weeks. The primary outcome measure was change from baseline glycated haemoglobin (HbA1c).Patients (N = 261) had modestly elevated HbA1c (mean ≈ 7.5%) most mild moderate renal impairment (estimated glomerular filtration rate range 43-103...
To evaluate the safety and efficacy of once-weekly subcutaneous semaglutide as monotherapy or combined with an oral antidiabetic drug (OAD) vs additional OAD added to background therapy in Japanese people type 2 diabetes (T2D) inadequately controlled on diet/exercise monotherapy.
Non-alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it known that the presence of mellitus leads to aggravation NAFLD. The aim this study was compare possible effects three kinds oral hypoglycemic agents on NAFLD mellitus.We carried out a prospective clinical trial (a randomized open-label study) patients A total 98 were randomly allocated either dapagliflozin (n = 32), pioglitazone 33) or glimepiride group, took these drugs for 28...
To evaluate the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy with existing antidiabetic agents in Japanese patients type 2 diabetes.TIMES was a phase 3, pivotal, open-label trial including diabetes inadequately controlled despite diet/exercise treatment single agent from one several available classes drugs along diet/exercise. All received 1000 mg twice-daily orally therapy. The primary endpoint (adverse events, laboratory results, ECG). secondary...
To determine genetic factors involved in diabetes susceptibility inbred strains of mice, we initially evaluated differences fed plasma glucose and insulin concentrations among six (AKR/J, C3H/HeJ, C57BL/6J, C57L/J, DBA/2J, SWR/J). There was considerable variation concentration, with C3H/HeJ mice the most tolerant (174 ± 7 mg/dl) C57BL/6J least (252 mg/dl, P &lt; .0001 vs. mice). Glycosylated hemoglobin (4.0 0.06%) also higher than that (3.52 0.06%, .0001). The concentration did not...
Liraglutide is a once-daily human glucagon-like peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes mellitus (T2DM). In Phase and 3 trials, largely conducted in populations European descent, liraglutide has been shown to lower HbA(1C), weight systolic blood pressure with low risk hypoglycaemia. This 3, 24-week, multi-centre, double-blind, double dummy, randomised parallel-group trial compared efficacy safety glibenclamide monotherapy Japanese subjects T2DM, inadequately...